Alatrofloxacin
![]() | |
Systematic (IUPAC) name | |
---|---|
7-[(1R,5S)-6-{[(2S)-1-{[(2S)-2-Aminopropanoyl]amino}-1-oxopropan-2-yl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid | |
Clinical data | |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Pregnancy category |
|
Routes of administration | Intravenous |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | 76% (trovafloxacin) |
Metabolism | Quickly hydrolyzed to trovafloxacin |
Biological half-life | 9 to 12 hours (trovafloxacin) |
Excretion | Fecal and renal (trovafloxacin) |
Identifiers | |
CAS Number |
146961-76-4 ![]() |
ATC code | none |
ChemSpider |
21243647 ![]() |
UNII |
7QVV6I50DT ![]() |
ChEMBL |
CHEMBL1201197 ![]() |
Chemical data | |
Formula | C26H25F3N6O5 |
Molar mass | 558.509 g/mol |
| |
| |
![]() ![]() |
Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt.[1]
Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.
See also
References
- ↑ "Center for Drug Evaluation and Research – Application Number: 020759/020760 – Chemistry Review(s)" (PDF). Food and Drug Administration. Retrieved 29 August 2014.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.